| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
PKD1 1 nM (IC50) PKD3 2 nM (IC50) PKD2 2.5 nM (IC50) PIM2 135.7 nM (IC50)
|
|---|---|
| ln Vitro |
CRT0066101 trihydrochloride (5 µM; 1 h) blocks basal and NT-induced pS916-PKD1/2 (activated PKD1/2) in Panc-1 and Panc-28 cells. CRT0066101 abolishes NT-induced Hsp27 (pS82-Hsp27) phosphorylation, attenuates PKD1-mediated NF-κB activation, and eliminates the expression of NF-κB-dependent proliferative and pro-survival proteins [1]. CRT0066101 trihydrochloride significantly inhibits Panc-1 cell proliferation with an IC50 value of 1 µM. CRT0066101 trihydrochloride induces apoptosis of Panc-1 cells 6-10-fold. CRT0066101 significantly reduced the proliferation of Colo357, Panc-1, MiaPaCa-2, and AsPC-1 cells, but had some effects on Capan-2 cells [1].
|
| ln Vivo |
CRT0066101 trihydrochloride (80 mg/kg/day; oral gavage; once daily; for 21 days) effectively blocked tumor growth in vivo in the Panc-1 orthotopic model[1]. CRT0066101 trihydrochloride (10 mg/kg, intraperitoneal injection, once every two days for three times) protected against LPS-induced pneumonia and reduced lung injury in C57BL/6J mice.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: Panc-1 and Panc-28 cells stimulation with neurotensin (NT) Concentration: 5 µM Incubation Duration: 1 h Experimental Results: Blocked both the basal and NT-induced pS916-PKD1/2 (activated PKD1/2). |
| Animal Protocol |
Animal/Disease Models: CR-UK nu/nu mice injected with Panc-1 cells[1]
Doses: 80 mg/kg/day Route of Administration: Oral gavage; once daily; for 21 days Experimental Results: Potently blocked tumor growth in vivo. Animal/Disease Models: LPS induced lung injury in C57BL/6J mice[3] Doses: 10 mg/kg Route of Administration: i.p., once every two days for 3 times Experimental Results: Inhibited the expression of MyD88 and TLR4, inhibited the phosphorylation of NF-κB, ERK and JNK. |
| References |
|
| Molecular Formula |
C18H25CL3N6O
|
|---|---|
| Molecular Weight |
447.79
|
| Exact Mass |
446.116
|
| CAS # |
1781742-22-0
|
| Appearance |
Typically exists as solids at room temperature
|
| LogP |
0
|
| SMILES |
Cl.Cl.Cl.OC1=CC=C(C2C=NN(C)C=2)C=C1C1=NC=CC(=N1)NC[C@@H](CC)N
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2332 mL | 11.1659 mL | 22.3319 mL | |
| 5 mM | 0.4466 mL | 2.2332 mL | 4.4664 mL | |
| 10 mM | 0.2233 mL | 1.1166 mL | 2.2332 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.